HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

South Korea · Delayed Price · Currency is KRW

6,600.00

+430.00 (6.97%)

Jul 14, 2026, 3:30 PM KST

-63.46% (1Y)

Market Cap	92.68B -64.0%
Revenue (ttm)	236.59B +72.6%
Net Income	3.72B +84.4%
EPS	113.17 +79.6%
Shares Out	14.04M
PE Ratio	58.32
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	554,415
Open	6,210.00
Previous Close	6,170.00
Day's Range	6,000.00 - 6,720.00
52-Week Range	6,000.00 - 22,250.00
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About HLB Pharmaceutical

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, par... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 047920

Full Company Profile

Financial Performance

In 2025, HLB Pharmaceutical's revenue was 205.58 billion, an increase of 49.97% compared to the previous year's 137.08 billion. Earnings were 4.57 billion, an increase of 126.35%.

Financial Statements